Milnacipran

Drug Profile

Milnacipran

Alternative Names: Dalcipran; F 2207; Impulsor; Ixel; JONCIA; Midacipran; Midalcipran; Milnacipran Pierre Fabre Medicament; Savella; TN 912; Toledomin

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pierre Fabre
  • Developer Allergan; Pierre Fabre
  • Class Amides; Amines; Analgesics; Antidepressants; Cyclopropanes; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibromyalgia; Major depressive disorder

Most Recent Events

  • 10 Apr 2015 Milnacipran is still registered for Fibromyalgia in Australia
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 10 Jul 2013 Pierre Fabre completes its phase II trial for Fibromyalgia in Switzerland (NCT00757679)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top